Nicholas A.J. Botwood Sells 31,235 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CMO Nicholas A.J. Botwood sold 31,235 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $18.14, for a total transaction of $566,602.90. Following the transaction, the chief marketing officer directly owned 60,885 shares in the company, valued at $1,104,453.90. The trade was a 33.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Nicholas A.J. Botwood also recently made the following trade(s):

• On Thursday, June 11th, Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total transaction of $617,040.00.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $18.25 on Friday. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.59 and a 52-week high of $25.59. The firm has a fifty day moving average of $21.06 and a 200-day moving average of $21.22. The firm has a market capitalization of $1.62 billion, a P/E ratio of -6.54 and a beta of 0.38. The company has a quick ratio of 5.06, a current ratio of 5.47 and a debt-to-equity ratio of 8.26.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. The business had revenue of $64.86 million during the quarter, compared to analyst estimates of $69.76 million. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The business’s revenue was up 224.3% on a year-over-year basis. During the same period last year, the business earned ($0.98) EPS. As a group, analysts predict that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Citigroup lifted their price objective on shares of Syndax Pharmaceuticals from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Stifel Nicolaus set a $45.00 price objective on shares of Syndax Pharmaceuticals in a research note on Friday, February 27th. Mizuho lowered their price objective on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Barclays lifted their price objective on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Finally, The Goldman Sachs Group lifted their price objective on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.55.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its position in shares of Syndax Pharmaceuticals by 2,698.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after acquiring an additional 2,564 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after acquiring an additional 1,922 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 26.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after acquiring an additional 893 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in shares of Syndax Pharmaceuticals in the second quarter worth approximately $66,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.